General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-07-26 | 2024-06 | 0.98 | N/A | N/A | N/A |
2024-04-25 | 2024-03 | 0.95 | 1.03 | 0.08 | 8.42% |
2024-02-08 | 2023-12 | 0.74 | 0.73 | -0.01 | -1.35% |
2023-11-09 | 2023-09 | 0.8 | 0.87 | 0.07 | 8.75% |
2023-07-28 | 2023-06 | 0.97 | 1.08 | 0.11 | 11.34% |
2023-04-27 | 2023-03 | 0.86 | 0.96 | 0.1 | 11.63% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-24 | Jefferies | Upgrade | Hold | Buy |
2023-09-07 | Erste Group | Downgrade | Buy | Hold |
2023-07-31 | BMO Capital | Upgrade | Outperform | Outperform |
2023-05-25 | Argus Research | Upgrade | Buy | Buy |
2023-04-12 | Argus Research | Upgrade | Buy | |
2023-01-04 | BMO Capital | Upgrade | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2020-12-15 | Ashley (Euan) | 700.00 | Bought | |
2017-09-24 | Bohen (Sean) | 24.77K | Bought | |
2019-04-28 | Eldracher (Deborah DiSanzo) | 1000 | Bought | |
2019-04-28 | McCoy (Sherilyn D) | 2.47K | Bought | |
2021-12-12 | Mok (Tony) | 4.00K | Bought | |
2022-05-04 | Rummelt (Andreas) | 0.00 | Sold |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Price (T.Rowe) Associates Inc | 52.85M | 3.78B | 2.01% |
2023-06-29 | Wellington Management Group, LLP | 49.13M | 3.52B | 1.87% |
2023-06-29 | Primecap Management Company | 44.08M | 3.15B | 1.68% |
2023-06-29 | Capital International Investors | 38.34M | 2.74B | 1.46% |
2023-06-29 | FMR, LLC | 22.82M | 1.63B | 0.87% |
2023-06-29 | Jennison Associates LLC | 21.81M | 1.56B | 0.83% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard/Primecap Fund | 25.66M | 1.84B | 0.98% |
2023-09-29 | Washington Mutual Investors Fund | 22.46M | 1.52B | 0.86% |
2023-05-30 | Vanguard/Wellington Fund Inc. | 17.32M | 1.27B | 0.66% |
2023-09-29 | American Mutual Fund Inc | 11.35M | 768.66M | 0.43% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 10.03M | 680.32M | 0.38% |
2023-06-29 | Price (T.Rowe) Health Sciences Fund | 7.02M | 502.22M | 0.27% |
Dividend | Date |
---|---|
0.985 | 2024-02-22 |
0.465 | 2023-08-10 |
0.965 | 2023-02-23 |
0.455 | 2022-08-11 |
0.965 | 2022-02-24 |
0.44 | 2021-08-12 |
Split | Date |
---|---|
2 : 1 | 2015-07-27 |
3 : 1 | 1998-04-08 |
I loved $AZN and held it earlier this year. Then I learned it pledged not to make any profit if its vaccine gets approved and distributed. That is the right thing for the world! But I decided no longer for me as an investor.
What?????????
$AZN less efficacy rate means less ppl willing to choose AZN vaccines! Will slip to $42.5 perhaps
To my friends... Look at LCA, it’s merging next week!
Get in to make some serious cash!
$NET was in poll position weeks ago now??
Oh uh. London is red
AZN LN start red 18 minutes ago.
No good
-.70.
Save the world and shares down?
patience. patience
Astrazenka in the right direction. It is not possible that an effective vaccine easy for transport and storage and cheap does will sit on the dusty shelf in the FDA basements or in Europe. I am convinced that our time investing in this company will come and the sun will rise and on us
I pray to the world for health and success my American friends
Have a great day everyone !
Vaccine and profits not here
AZN !
Wait. The sun ️ will come!
Big news in Australia about AZN. Back it and it will back you.
https://www.bnnbloomberg.ca/vaccine-may-halt-severe-cases-new-japan-measures-virus-update-1.1526820
Astra Shot Data Hint at Halting Severe Covid (5:55 p.m. NY)
The leader of the U.S. government’s coronavirus vaccine program said AstraZeneca Plc found that 16 participants who received a placebo in its clinical trial contracted severe Covid-19, a sign that the shot could block the worst cases of disease.
The British drugmaker and its partner, the University of Oxford, said earlier Monday that none of the trial participants who received the vaccine had become severely ill, and that none of the patients in that group were hospitalized.
“That’s very important,” said Moncef Slaoui, chief scientific adviser to Operation Warp Speed, in an interview with Bloomberg News. “It’s exciting.”